Global Non-Invasive Prenatal Testing (NIPT) Market Assessment, By Product [Instruments, Consumables], By Method, [Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Cell-free DNA (cfDNA), Others], By Application [Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), Turner Syndrome (Monosomy X), Others], By End-user [Hospitals, Diagnostic Laboratories, Clinics], By Region, Opportunities and Forecast, 2018-2032F

Global non-invasive prenatal testing (NIPT) market is projected to witness a CAGR of 14.70% during the forecast period 2025-2032, growing from USD 6.91 billion in 2024 to USD 20.70 billion in 2032.

Non-Invasive Prenatal Testing (NIPT) Market Size, Opportunities and Forecast, 2018-2032F

Global Non-Invasive Prenatal Testing (NIPT) Market is projected to witness a CAGR of 14.70% during the forecast period 2025-2032, growing from USD 6.91 billion in 2024 to USD 20.70 billion in 2032. Increased demand for safer screening options, increased maternal age, and an increased awareness of genetic disorders are the key drivers of the non-invasive prenatal testing (NIPT) market. Advances in NIPT technology, supportive reimbursement policies, and strategic partnerships will further help to fuel the market&rsquo;s growth.
NIPT is a screening test for fetal chromosomal abnormalities that is conducted using a non-invasive maternal blood sample. It analyzes mainly fetal cell-free DNA from the maternal bloodstream, detecting especially trisomy disorders such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13), as well as many other sex chromosome disorders. NIPT is usually performed during 10 weeks of gestation and is proven to have an accuracy level greater than 99%. Myriad.
Ongoing expansion of non-invasive prenatal testing services across regions underscores the significant growth of the market. In October 2024, Yourgene Health Ltd, part of the Novacyt group, and Genetix S.A. launched its first non-invasive prenatal testing service in Colombia. This is the first expansion of Yourgene Health Ltd in Latin America, an area historically underserved in advanced prenatal diagnostics.
The rising requirement for non-invasive testing is bolstering the launch of new products. The efforts by the companies to strengthen their diagnostics portfolio are further fueling the market&rsquo;s growth. For instance, in March 2024, BillionToOne, Inc., a molecular diagnostics company, launched BabyPeek. This non-invasive test detects non-medical traits of a baby, like eye color and food preferences, from maternal blood. Moreover, in April 2024, Strand Life Sciences Pvt. Ltd, a Reliance Industries Ltd. subsidiary, expanded its prenatal diagnostics portfolio through the launch of CNSeq and MaatriSeq tests in India. These streamlined, precision tests, developed to meet Indian-specific requirements, support India's rare disease program and are most likely to fuel the market&rsquo;s expansion in the coming years.
<h2 style="text-align: justify;">Increasing Prevalence of Chromosomal Abnormalities Boosts Market Demand</h2>
The high prevalence of chromosomal abnormalities, often the main cause of miscarriage, is driving the demand for NIPT. A study published in November 2023 in Nature Medicine (Springer Nature Limited) found that 50.4% of spontaneous miscarriages are attributed to problems with chromosomes and the rising maternal and paternal ages. Conditions such as Down's syndrome, Edwards syndrome, and Patau's syndrome have become increasingly prevalent among elderly mothers, resulting in growing demand for early safety testing procedures. NIPT offers a non-invasive blood test alternative to traditional testing, reassuring parents and reducing risks associated with traditional testing.
Furthermore, the growth of the NIPT market is fueled by rising awareness, as couples tend to engage in proactive screening. For instance, in September 2024, KK Women's and Children's Hospital (KKH)&nbsp;partnered with Temasek Foundation to launch a genetic screening&nbsp;program - Temasek Foundation PREDICT (PaREnthood genetic DIsease Carrier Test) Programme in Singapore.&nbsp;The program is designed to screen over 80 severe recessive genetic disorders&nbsp;and&nbsp;provides&nbsp;free genetic counseling and&nbsp;testing services. This program is also expected to raise awareness among couples, address their genetic health needs, and help prospective parents in informed decision-making regarding family planning, thus supporting the market's growth.
<h2 style="text-align: justify;">Advancements in NIPT Drive Market Growth</h2>
Advancements in NIPT, such as increased sensitivity and specificity, allow for better detection of genetic abnormalities, which in turn drives the growth of the market. Improvements in gene sequencing techniques and advanced bioinformatics analysis of cell-free DNA can expand the range of detectable conditions. The increased sensitivity and specificity make it a preferred choice for expectant parents as it can give more accurate results. Therefore, such advancements create more demand for enhanced NIPT.
Additionally, various medical testing companies are also working on introducing advanced testing solutions to enhance patient convenience and combat the various challenges currently being faced by the healthcare sector. In May 2024, Natera, Inc. launched a cfDNA-based test determining fetal RhD status as early as nine weeks to address the current-day shortages of RhIg therapy. Unlike most NIPT labs, Natera's test evaluates fetal RhD and accurately identifies complex variants. This innovation, validated with more than 650 confirmed outcomes, reached 100% sensitivity and over 99% specificity, further supporting safer patient care. Such introductions are expected to enhance the confidence of healthcare professionals and patient populations in novel NIPT&rsquo;s and provide lucrative growth opportunities to the market.
<h2 style="text-align: justify;">Novel Product Launches Support Market Expansion</h2>
The growth in the non-invasive prenatal testing (NIPT) market is primarily driven by the frequent launches of new tests. This trend highlights that more and more people are embracing NIPTs due to their relatively safe and accurate nature. Manufacturers now focus on developing highly advanced NIPTs and strategic partnerships to enhance their market presence. Innovations in testing are expected to ensure better accuracy, wider testing abilities, and easier accessibility, promoting the market's growth. Frequent release of NIPTs keeps the market highly and actively responsive to change as the healthcare conditions evolve, further enabling healthy growth in the NIPT industry. For instance, in April 2023, Mediclinic Southern Africa (Pty) Ltd. introduced a safe and non-invasive prenatal test for expectant parents as part of their DNA-based testing services. The new NIPT builds on the huge success of their previous testing launch and will detect common chromosomal conditions that exist in the fetus. It uses a simple maternal blood test that can identify potential genetic risks as early as nine weeks. Thus, it ensures early disease detection and increases patient confidence in novel diagnostic solutions, supporting the expansion of the market.
<h2 style="text-align: justify;">Consumables Dominate the Non-Invasive Prenatal Testing (NIPT) Market</h2>
The consumables segment holds the largest share in the non-invasive prenatal testing (NIPT) market mainly because of the enormous demand for consumables, reagents, and assay kits for the successful completion of the testing procedures. These products find extensive applications in the clinical setting. Additionally, the rising adoption of NIPTs by expectant parents due to increasing awareness about the importance of genetic screening and growing awareness about chromosomal anomalies is further propelling the requirement for consumables.
Meanwhile, instruments account for the second leading share of the market. Novel product launches in various regions across the globe support the growth of this segment. For instance,&nbsp;in November 2023, Yourgene Health Ltd (Yourgene Health), a subsidiary of Novacyt UK Holdings Ltd, deployed the first NIPT workflow in Morocco at Centre de Biologie Rabat Hay Riad, which is based on the IONA test. Brand-named the COSY test by Laboriad, this high-tech screening device identifies risks in terms of trisomy 21, 18, and 13 within three days.
<h2 style="text-align: justify;">North America Accounts for Major Share in the Non-Invasive Prenatal Testing (NIPT) Market</h2>
North America leads the global NIPT market due to the increasing adoption of non-invasive prenatal testing and the high prevalence of chromosomal abnormalities among neonates in the region. Key North American companies commercially provide advanced NIPT solutions, increasing the accessibility of NIPTs across the United States and Canada. Growing awareness among pregnant couples and healthcare professionals has increased demand; expanded insurance coverage in the U.S. has also made NIPT more accessible, thereby reducing out-of-pocket payments. Furthermore, other enabling policies and well-developed reimbursement structures further facilitate adoption, cementing North America's leadership in the global NIPT market and ensuring the widespread availability of these crucial prenatal screening solutions. The increasing launch of novel technologies and services in the region also supports the market&rsquo;s expansion. For instance, in May 2024, Igentify Ltd., in New York, launched a new NIPT and pharmacogenomics service on its Digital Genetic Assistant platform, strengthening support for patients and clinicians.
<a href="https://www.marketsandata.com/industry-reports/non-invasive-prenatal-testing-nipt-market/sample-request">Download Free Sample Report</a>
Future Market Scenario (2025-2032F)
The NIPT market is expected to grow further due to ongoing technological advancements and an increasing need for precise prenatal testing. Growing awareness about genetic disorders and their expanded benefits should help reinforce the significance of NIPT in prenatal health management.
Furthermore, technological advancements in non-invasive prenatal testing, especially those coming through sequence technologies such as next-generation sequencing, are expected to provide lucrative growth opportunities to the market in the future. For example, Illumina NIPT uses whole-genome sequencing through cell-free DNA to detect chromosomal abnormalities with high sensitivity and specificity. The availability of novel technologies with increased accuracy is further expected to fuel the market&rsquo;s expansion.
Moreover, in September 2023, Gene Solutions, JSC, a fast-growing Vietnamese biotech firm, received USD 21 million in funds to expand its presence in Southeast Asia. Such investments are also expected to provide significant opportunities for the market&rsquo;s growth as they allow companies to expand their geographical presence and focus on developing novel technologies and products.
Report Scope
&ldquo;Non-Invasive Prenatal Testing (NIPT) Market Assessment, Opportunities and Forecast, 2018-2032F&rdquo;,&nbsp;is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the&nbsp;global non-invasive prenatal testing (NIPT) market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.
<table>
<tbody>
<tr>
<td width="301">
Report Attribute
</td>
<td width="301">
Details
</td>
</tr>
<tr>
<td width="301">
Base Year of the Analysis
</td>
<td width="301">
2024
</td>
</tr>
<tr>
<td width="301">
Historical Period
</td>
<td width="301">
2018-2023
</td>
</tr>
<tr>
<td width="301">
Forecast Period
</td>
<td width="301">
2025-2032
</td>
</tr>
<tr>
<td width="301">
Projected Growth Rate
</td>
<td width="301">
CAGR of 14.70% between 2025 and 2032
</td>
</tr>
<tr>
<td width="301">
Revenue Forecast in 2032
</td>
<td width="301">
USD 20.70 billion
</td>
</tr>
<tr>
<td width="301">
Segments Covered
</td>
<td width="301">
Product, Method, Application, End-user
</td>
</tr>
<tr>
<td width="301">
Regions Covered
</td>
<td width="301">
North America, Europe, South America, Asia-Pacific, Middle East and Africa
</td>
</tr>
<tr>
<td width="301">
Key Companies Profile
</td>
<td width="301">
Illumina, Inc., Eurofins LifeCodexx GmbH, Myriad Genetics, Inc., Natera, Inc., CENTOGENE N.V., PerkinElmer Inc., F. Hoffmann-La Roche Ltd., MedGenome Labs Limited, Laboratory Corporation of America Holdings, BGI Genomics Co., Ltd.
</td>
</tr>
<tr>
<td width="301">
Customization Scope
</td>
<td width="301">
15% free report customization with purchase
</td>
</tr>
<tr>
<td width="301">
Pricing and Purchase Options
</td>
<td width="301">
Avail the customized purchase options to fulfill your precise research needs
</td>
</tr>
<tr>
<td width="301">
Delivery Format
</td>
<td width="301">
PDF and Excel through email (subject to the license purchased)
</td>
</tr>
</tbody>
</table>
In the report, the&nbsp;global non-invasive prenatal testing (NIPT) market&nbsp;has been segmented into the following categories:&nbsp;
<ul style="text-align: justify;">
<li>By Product
<ul>
<li>Instruments</li>
<li>Consumables
<ul>
<li>Kits</li>
<li>Reagents</li>
</ul>
</li>
<li>By Method
<ul>
<li>Next Generation Sequencing (NGS)</li>
<li>Polymerase Chain Reaction (PCR)</li>
<li>Cell-free DNA (cfDNA)</li>
<li>Others</li>
</ul>
</li>
<li>By Application
<ul>
<li>Down Syndrome (Trisomy 21)</li>
<li>Edwards Syndrome (Trisomy 18)</li>
<li>Patau Syndrome (Trisomy 13)</li>
<li>Turner Syndrome (Monosomy X)</li>
<li>Others</li>
</ul>
</li>
<li>By End-user
<ul>
<li>Hospitals</li>
<li>Diagnostic Laboratories</li>
<li>Clinics</li>
</ul>
</li>
<li>By Region
<ul>
<li>North America</li>
<li>Europe</li>
<li>Asia-Pacific</li>
<li>South America</li>
<li>Middle East and Africa</li>
</ul>
</li>
</ul>
</li>
</ul>
Key Players Landscape and Outlook
The key players in the NIPT market are enhancing their positions through investments in the procurement of significant product portfolios and concentrated efforts toward research and development activities. Strategic alliances, new product launches, and acquisitions allow them to expand their market presence and result in sustained leadership.
In January&nbsp;2024, BGI Genomics Co. Ltd.&nbsp;launched&nbsp;the ultra-fast, non-invasive prenatal testing product&nbsp;NIFTY,&nbsp;which&nbsp;is designed to utilize small as well as medium throughput&nbsp;of&nbsp;the&nbsp;DNBSEQ-G99 platform. The platform helps get quick&nbsp;and&nbsp;accurate&nbsp;results for timely genetic counseling and prenatal diagnostics.&nbsp;The&nbsp;innovation&nbsp;further&nbsp;bolsters the company's&nbsp;position in the&nbsp;market.
In January 2024, Natera, Inc. acquired the reproductive health assets of Invitae Corporation, including its non-invasive prenatal and carrier screening business. The upfront payment was made of USD 10 million, while the milestone payments could amount to USD 42.5 million. Natera views the acquisition of Invitae&rsquo;s reproductive health assets as a strategy that expands its non-invasive prenatal screening portfolio and turns the company into market leadership.
Key Players Operating in the&nbsp;Global Non-Invasive Prenatal Testing (NIPT) Market are:
<ul style="text-align: justify;">
<li>Illumina, Inc.</li>
<li>Eurofins LifeCodexx GmbH</li>
<li>Myriad Genetics, Inc.</li>
<li>Natera, Inc.</li>
<li>CENTOGENE N.V.</li>
<li>PerkinElmer Inc.</li>
<li>Hoffmann-La Roche Ltd</li>
<li>MedGenome Labs Limited</li>
<li>Laboratory Corporation of America Holdings</li>
<li>BGI Genomics Co., Ltd.</li>
</ul>
Markets and Data&rsquo;s reports answer the following questions:
<ul style="text-align: justify;">
<li>What is the current and future market size of the product/service in question globally or specific to different countries?</li>
<li>How are the markets divided into different product/service segments and the market size and growth of each segment?</li>
<li>What is the market potential of different product segments and their investment case?</li>
<li>How are the markets predicted to develop in the future and what factors will drive or inhibit growth?</li>
<li>What is the business environment and regulatory landscape specific to the product/service?</li>
</ul>
If you can't find what you're searching for or have any custom requirements for global non-invasive prenatal testing (NIPT) market, you may approach our team at&nbsp;<a href="mailto:info@marketsandata.com">info@marketsandata.com</a>.

Global Non-Invasive Prenatal Testing (NIPT) Market Assessment, Opportunities and Forecast, 2018-2032F

Key drivers influencing the growth of the non-invasive prenatal testing (NIPT) market include increasing demand for safer screening options due to the rising chromosomal abnormalities, increasing maternal age, and growing awareness of genetic disorders.

Table of Contents
<ol>
<li>Project Scope and Definitions</li>
<li>Research Methodology</li>
<li>Executive Summary</li>
<li>Global Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F
<ul>
<li>Market Size Analysis &amp; Forecast
<ul>
<li>By Value</li>
</ul>
</li>
<li>Market Share Analysis &amp; Forecast
<ul>
<li>By Product
<ul>
<li>Instruments</li>
<li>Consumables
<ul>
<li>Kits</li>
<li>Reagents</li>
</ul>
</li>
<li>By Method
<ul>
<li>Next Generation Sequencing (NGS)</li>
<li>Polymerase Chain Reaction (PCR)</li>
<li>Cell-free DNA (cfDNA)</li>
<li>Others</li>
</ul>
</li>
<li>By Application
<ul>
<li>Down Syndrome (Trisomy 21)</li>
<li>Edwards Syndrome (Trisomy 18)</li>
<li>Patau Syndrome (Trisomy 13)</li>
<li>Turner Syndrome (Monosomy X)</li>
<li>Others</li>
</ul>
</li>
<li>By End-user
<ul>
<li>Hospitals</li>
<li>Diagnostic Laboratories</li>
<li>Clinics</li>
</ul>
</li>
<li>By Region
<ul>
<li>North America</li>
<li>Europe</li>
<li>Asia-Pacific</li>
<li>South America</li>
<li>Middle East and Africa</li>
</ul>
</li>
<li>By Company Market Share Analysis (Top 5 Companies and Others &ndash; By Value, 2024)</li>
</ul>
</li>
<li>Market Map Analysis, 2024
<ul>
<li>By Product</li>
<li>By Method</li>
<li>By Application</li>
<li>By End-user</li>
<li>By Region</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ol>
<ol start="5">
<li>North America Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F*
<ul>
<li>Market Size Analysis &amp; Forecast
<ul>
<li>By Value</li>
</ul>
</li>
<li>Market Share Analysis &amp; Forecast
<ul>
<li>By Product
<ul>
<li>Instruments</li>
<li>Consumables
<ul>
<li>Kits</li>
<li>Reagents</li>
</ul>
</li>
<li>By Method
<ul>
<li>Next Generation Sequencing (NGS)</li>
<li>Polymerase Chain Reaction (PCR)</li>
<li>Cell-free DNA (cfDNA)</li>
<li>Others</li>
</ul>
</li>
<li>By Application
<ul>
<li>Down Syndrome (Trisomy 21)</li>
<li>Edwards Syndrome (Trisomy 18)</li>
<li>Patau Syndrome (Trisomy 13)</li>
<li>Turner Syndrome (Monosomy X)</li>
<li>Others</li>
</ul>
</li>
<li>By End-user
<ul>
<li>Hospitals</li>
<li>Diagnostic Laboratories</li>
<li>Clinics</li>
</ul>
</li>
<li>By Country Share
<ul>
<li>United States</li>
<li>Canada</li>
<li>Mexico</li>
</ul>
</li>
<li>Country Market Assessment
<ul>
<li>United States Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F*
<ul>
<li>Market Size Analysis &amp; Forecast
<ul>
<li>By Value</li>
</ul>
</li>
<li>Market Share Analysis &amp; Forecast
<ul>
<li>By Product
<ul>
<li>Instruments</li>
<li>Consumables
<ul>
<li>Kits</li>
<li>Reagents</li>
</ul>
</li>
<li>By Method
<ul>
<li>Next Generation Sequencing (NGS)</li>
<li>Polymerase Chain Reaction (PCR)</li>
<li>Cell-free DNA (cfDNA)</li>
<li>Others</li>
</ul>
</li>
<li>By Application
<ul>
<li>Down Syndrome (Trisomy 21)</li>
<li>Edwards Syndrome (Trisomy 18)</li>
<li>Patau Syndrome (Trisomy 13)</li>
<li>Turner Syndrome (Monosomy X)</li>
<li>Others</li>
</ul>
</li>
<li>By End-user
<ul>
<li>Hospitals</li>
<li>Diagnostic Laboratories</li>
<li>Clinics</li>
</ul>
</li>
<li>Canada</li>
<li>Mexico</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ol>
*All segments will be provided for all regions and countries covered
<ol start="6">
<li>Europe Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F
<ul>
<li>Germany</li>
<li>France</li>
<li>Italy</li>
<li>United Kingdom</li>
<li>Russia</li>
<li>Netherlands</li>
<li>Spain</li>
<li>Turkey</li>
<li>Poland</li>
</ul>
</li>
<li>Asia-Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F
<ul>
<li>India</li>
<li>China</li>
<li>Japan</li>
<li>Australia</li>
<li>Vietnam</li>
<li>South Korea</li>
<li>Indonesia</li>
<li>Philippines</li>
</ul>
</li>
<li>South America&nbsp;Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F
<ul>
<li>Brazil</li>
<li>Argentina</li>
</ul>
</li>
<li>Middle East and Africa&nbsp;Non-invasive Prenatal Testing (NIPT) Market Outlook, 2018-2032F
<ul>
<li>Saudi Arabia</li>
<li>UAE</li>
<li>South Africa</li>
</ul>
</li>
<li>Demand Supply Analysis</li>
<li>Value Chain Analysis</li>
<li>Porter&rsquo;s Five Forces Analysis</li>
<li>PESTLE Analysis</li>
<li>Pricing Analysis</li>
<li>Market Dynamics
<ul>
<li>Market Drivers</li>
<li>Market Challenges</li>
</ul>
</li>
<li>Market Trends and Developments</li>
<li>Regulatory Framework and Innovation
<ul>
<li>Regulatory Approvals</li>
</ul>
</li>
<li>Patent Landscape</li>
<li>Case Studies</li>
<li>Competitive Landscape
<ul>
<li>Competition Matrix of Top 5 Market Leaders</li>
<li>SWOT Analysis for Top 5 Players</li>
<li>Key Players Landscape for Top 10 Market Players
<ul>
<li>Illumina, Inc.
<ul>
<li>Company Details</li>
<li>Key Management Personnel</li>
<li>Products and Services</li>
<li>Financials (As Reported)</li>
<li>Key Market Focus and Geographical Presence</li>
<li>Recent Developments/Collaborations/Partnerships/Mergers and Acquisition</li>
</ul>
</li>
<li>Eurofins LifeCodexx GmbH</li>
<li>Myriad Genetics, Inc.</li>
<li>Natera, Inc.</li>
<li>CENTOGENE N.V.</li>
<li>PerkinElmer Inc.</li>
<li>Hoffmann-La Roche Ltd</li>
<li>MedGenome Labs Limited</li>
<li>Laboratory Corporation of America Holdings</li>
<li>BGI Genomics Co., Ltd.</li>
</ul>
</li>
</ul>
</li>
</ol>
*Companies mentioned above&nbsp;DO NOT&nbsp;hold any order as per market share and can be changed as per information available during research work.
<ol start="21">
<li>Strategic Recommendations</li>
<li>About Us and Disclaimer</li>
</ol>

FAQs

Industry Reports

Blogs

Case Studies

Industry News

Press Release

Infographics